Pragmatic Randomized Clinical Trial of Early Dronedarone versus Usual Care to Change and Improve Outcomes in Persons with First-Detected Atrial Fibrillation (CHANGE AFIB)
Study of Dronedarone in Patients with Atrial Fibrillation (AF)
Sponsor: American Heart Association
Enrolling: Male and Female Patients
IRB Number: AAAU4696
U.S. Govt. ID: NCT05130268
Contact: Esteban Ceballos: / ec3539@cumc.columbia.edu
Additional Study Information: Atrial fibrillation (AFib) is an arrhythmia (abnormal heart rhythm) that causes the heart's upper chambers (the atria) to beat very fast and irregularly. The purpose of this study is to determine if early study treatment with the medicine dronedarone is more effective than usual care alone for the prevention of unplanned cardiovascular hospitalization. A computer will randomly assign you (like the flip of a coin) to receive either the study intervention or usual care. Both you and your study doctors will know to which group you have been assigned. The study intervention is the oral (by mouth) medication dronedarone. Dronedarone is a heart rhythm medicine. The usual care group will be prescribed medicines that they would receive as part of their usual car.
This study is closed
Investigator
Elaine Wan, MD
Do You Qualify?
Are you at least 21 years old? Yes No
Have you been diagnosed with Atrial Fibrillation (AF)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Esteban Ceballos
ec3539@cumc.columbia.edu